Homepage
Medication Guide
What are the Precautions for Enasidenib Administration?
Enasidenib is an isocitrate dehydrogenase-2 (IDH2) inhibitor that offers a targeted treatment option for patients with relapsed or refractory acute myeloid leukemia (AML).What are the Precautions for ...
507
Tuesday, December 23rd, 2025, 10:21
Dosage and Administration, Recommended Dose of Enasidenib
As an isocitrate dehydrogenase-2 (IDH2) inhibitor, Enasidenib offers a targeted treatment option for patients with relapsed or refractory acute myeloid leukemia (AML). Its unique mechanism of action t...
509
Tuesday, December 23rd, 2025, 10:09
What Are the Indications for Enasidenib?
Enasidenib is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor, which was first approved for marketing in the United States in 2017 for the treatment of specific types of acute myeloid leukemia (AM...
510
Tuesday, December 23rd, 2025, 09:30
What Are the Procurement Channels for Enasidenib?
Enasidenib is a targeted drug indicated for relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutation, and its trade name is IDHIFA. Given its specific indications and prescription-only n...
504
Tuesday, December 23rd, 2025, 09:25
Adverse Reactions of Pralsetinib (Gavreto)
Pralsetinib (Gavreto) is a targeted therapy for RET fusion-positive tumors. While delivering therapeutic benefits to patients, it is also associated with potential risks that cannot be ignored.Adverse...
512
Monday, December 22nd, 2025, 09:44
What Are the Precautions for Pralsetinib (Gavreto) Administration?
Pralsetinib (Gavreto) is a new-generation highly selective RET inhibitor, offering a breakthrough treatment option for patients with RET fusion-positive non-small cell lung cancer and thyroid cancer.W...
507
Monday, December 22nd, 2025, 09:41
Dosage and Administration, Recommended Dose of Pralsetinib (Gavreto)
Pralsetinib (Gavreto) is a kinase inhibitor targeting RET gene fusions, and it demonstrates significant value in the treatment of metastatic RET fusion-positive non-small cell lung cancer and thyroid ...
508
Monday, December 22nd, 2025, 09:34
What Are the Indications for Pralsetinib (Gavreto)?
Pralsetinib (Gavreto) is an oral kinase inhibitor primarily indicated for the treatment of specific malignant tumors associated with RET gene alterations. Manufactured by Genentech, this drug first re...
507
Monday, December 22nd, 2025, 09:26
What Are the Purchase Channels for Pralsetinib (Gavreto)?
Pralsetinib (Gavreto) is a precision RET kinase inhibitor and has become an important treatment option for cancers associated with RET gene alterations. As a prescription medication, the purchase of p...
506
Monday, December 22nd, 2025, 09:20
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...
508
Friday, December 19th, 2025, 11:49
23 / 207
2061 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved